137 related articles for article (PubMed ID: 7847107)
1. Effect of two different progestins (cyproterone acetate and norgestrel), administered in a cyclical estradiol valerate regimen, on markers of bone turnover.
Prelević GM; Beljić T; Balint-Perić L; Petrović J; Elliesen J
Gynecol Endocrinol; 1994 Sep; 8(3):209-14. PubMed ID: 7847107
[TBL] [Abstract][Full Text] [Related]
2. Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy.
Thomsen K; Riis BJ; Johansen JS; Christiansen C; Rødbro P
Gynecol Endocrinol; 1987 Jun; 1(2):169-75. PubMed ID: 2972170
[TBL] [Abstract][Full Text] [Related]
3. Continuous oestrogen-progestogen treatment and bone metabolism in post-menopausal women.
Riis BJ; Johansen J; Christiansen C
Maturitas; 1988 May; 10(1):51-8. PubMed ID: 3041248
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two hormone replacement regimens--influence on lipoproteins and bone mineral content.
Hirvonen E; Elliesen J; Schmidt-Gollwitzer K
Maturitas; 1990 Jun; 12(2):127-36. PubMed ID: 2147736
[TBL] [Abstract][Full Text] [Related]
5. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis.
Lems WF; Gerrits MI; Jacobs JW; van Vugt RM; van Rijn HJ; Bijlsma JW
Ann Rheum Dis; 1996 May; 55(5):288-93. PubMed ID: 8660101
[TBL] [Abstract][Full Text] [Related]
6. Endocrine effects in Asian postmenopausal women, treated with SH D 461 M and Prempak-C.
Goh HH; McCarthy TG; Dramusic V; Costales A; Junge W; Ratnam SS
Maturitas; 1995 Jan; 21(1):17-25. PubMed ID: 7731378
[TBL] [Abstract][Full Text] [Related]
7. Effect of estradiol valerate alone or in association with cyproterone acetate upon vascular function of postmenopausal women at increased risk for cardiovascular disease.
Vitale C; Fini M; Leonardo F; Rossini P; Cerquetani E; Onorati D; Rosano GM
Maturitas; 2001 Dec; 40(3):239-45. PubMed ID: 11731185
[TBL] [Abstract][Full Text] [Related]
8. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
Marslew U; Overgaard K; Riis BJ; Christiansen C
Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
[TBL] [Abstract][Full Text] [Related]
9. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
[TBL] [Abstract][Full Text] [Related]
10. Effects of conjugated equine oestrogens with and without the addition of cyclical norgestrel on serum and urine electrolytes, and the biochemical indices of bone metabolism and liver function.
Fletcher CD; Farish E; Dagen MM; Allam BF; Hart DM
Maturitas; 1988 Mar; 9(4):347-57. PubMed ID: 2837620
[TBL] [Abstract][Full Text] [Related]
11. The effect of intranasal salmon calcitonin on biochemical parameters of bone turnover in postmenopausal women.
Balint-Perić LA; Prelević GM; Beslagić Z; Petrović J
Gynecol Endocrinol; 1994 Dec; 8(4):241-5. PubMed ID: 7709763
[TBL] [Abstract][Full Text] [Related]
12. Endocrine effects in Asian postmenopausal women treated with SH D 461 M and Prempak-C.
Goh HH; McCarthy TG; Dramusic V; Costales A; Junge W; Ratnam SS
Maturitas; 1994 Dec; 20(2-3):165-73. PubMed ID: 7715469
[TBL] [Abstract][Full Text] [Related]
13. Serum lipids, lipoproteins, and apolipoproteins during postmenopausal estrogen replacement therapy combined with either 19-nortestosterone derivatives or 17-hydroxyprogesterone derivatives.
Haarbo J; Hassager C; Jensen SB; Riis BJ; Christiansen C
Am J Med; 1991 May; 90(5):584-9. PubMed ID: 1827568
[TBL] [Abstract][Full Text] [Related]
14. Influence of two hormone replacement therapy regimens, oral oestradiol valerate and cyproterone acetate versus transdermal oestradiol and oral dydrogesterone, on lipid metabolism.
Schram JH; Boerrigter PJ; The TY
Maturitas; 1995 Sep; 22(2):121-30. PubMed ID: 8538480
[TBL] [Abstract][Full Text] [Related]
15. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
16. The effect of oestradiol valerate and cyclic oestradiol valerate/DL-norgestrel on calcium metabolism.
Crilly RG; Marshall DH; Nordin BE
Postgrad Med J; 1978; 54 Suppl 2():47-9. PubMed ID: 740580
[TBL] [Abstract][Full Text] [Related]
17. Nomegestrol acetate may enhance the skeletal effects of estradiol on biochemical markers of bone turnover in menopausal women after a 12-week treatment period.
Nguyên-Pascal ML; Thomas JL; Bergougnoux L; Garnero P; Drapier-Faure E; Delmas PD
Climacteric; 2005 Jun; 8(2):136-45. PubMed ID: 16096169
[TBL] [Abstract][Full Text] [Related]
18. Comparison of serum osteocalcin with total and bone specific alkaline phosphatase and urinary hydroxyproline:creatinine ratio in patients with Paget's disease of bone.
Kaddam IM; Iqbal SJ; Holland S; Wong M; Manning D
Ann Clin Biochem; 1994 Jul; 31 ( Pt 4)():327-30. PubMed ID: 7979096
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy with estradiol valerate and cyproterone acetate: effects on endothelium-dependent vasodilatation and arterial wall compliance.
Mares P; Dauzat M; Abramovici Y
Maturitas; 2002 May; 42(1):45-53. PubMed ID: 12020979
[TBL] [Abstract][Full Text] [Related]
20. Time-dependent variations in bone turnover parameters during 2 months' cyclic treatment with different doses of combined estrogen and progestogen in postmenopausal women.
Johansen JS; Jensen SB; Riis BJ; Christiansen C
Metabolism; 1990 Nov; 39(11):1122-6. PubMed ID: 2233271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
